SCHEMBL12786144

SCHEMBL12786144

COCCOc1cccc2[nH]c3c4c(c5c(c3c12)C(=O)N(CN1CCN(C)CC1)C5=O)CCC4

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 6/20 0.82
▸ PARP2 Q9UGN5 1/20 0.82
▸ PDE5A O76074 2/20 0.35
▸ BCHE P06276 1/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ NOS3 P29474 2/20 0.35
▸ NOS1 P29475 2/20 0.35
▸ NOS2 P35228 2/20 0.35
▸ PTGS2 P35354 3/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ TIPARP Q7Z3E1 1/20 0.32
▸ PTGS1 P23219 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12786154 0.92 PARP1 (0.78) PARP1PARP2PDE5ABCHECHRNB2
SCHEMBL14980890 0.92 PARP1 (0.80) PARP1PARP2PDE5ABCHECHRNB2
Cep-9722 SCHEMBL29374944 0.90 PARP1 (1.00) PARP1PARP2PDE5APDE4DPDE10A
Cep-9722 SCHEMBL3359996 0.90 PARP1 (1.00) PARP1PARP2PDE5APDE4DPDE10A
SCHEMBL12786188 0.83 PARP1 (0.86) PARP1PARP2PDE5APDE4DPDE10A
SCHEMBL14346230 0.83 PARP1 (0.76) PARP1PARP2PTGS2PTGS1ALDH1A1
SCHEMBL3361926 0.80 PARP1 (0.81) PARP1PARP2PDE5APDE4DPDE10A
SCHEMBL12846276 0.79 PARP1 (0.55) PARP1PARP2
SCHEMBL12786190 0.78 PARP1 (0.74) PARP1PARP2PDE5APDE4DPDE10A
SCHEMBL14169516 0.74 PARP1 (0.71) PARP1PARP2PDE5APDE4DPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066324-B1 CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS CEPHALON INC (US) 2013-05-29 — — EP disclosed
US-20110059959-A1 NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF CEPHALON, INC. (US) 2011-03-10 — — US disclosed
US-20110059959-A1 NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF CEPHALON, INC. (US) 2011-03-10 — — US disclosed
WO-2007149451-A2 CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS CEPHALON, INC. (US) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059959-A1 NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF MLKL, PARP3, PARP1 PARP1 3/4885PARP2 5/4885PDE5A 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback